IDF 2021
BANGKOK
ONSITE & ONLINE
6-9 DECEMBER

ADVANCE PROGRAMME
CALL FOR ABSTRACTS

www.idf.org/congress
The International Diabetes Federation (IDF) is an alliance of 240 national diabetes associations in more than 160 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. IDF’s mission is to promote diabetes care, prevention and a cure worldwide. IDF is engaged in action to tackle diabetes from the local to the global level - from programmes at community level to worldwide awareness and advocacy initiatives.

IDF is a diverse and inclusive multi-cultural network of national diabetes associations and an authoritative global voice in non-communicable diseases.

The federation’s activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization (WHO).

For more information please visit www.idf.org.
TABLE OF CONTENTS

Welcome address 4
Why Attend 5
Congress committees 6
Key dates 8
Congress-at-a-glance 9
Opening hours 10
Programme Committee 11
Learning objectives 14
Call for abstracts 17
Registration 20
Accommodation, travel and visa 22
Contact 26

Please note, information in the Advance Programme is subject to change.
It gives me great pleasure to invite you to the International Diabetes Federation (IDF) Congress 2021 in Bangkok, Thailand.

At the time of writing, we continue to live difficult times due to the COVID-19 pandemic that has disrupted the lives of billions across the world. People with diabetes have been among those most affected. We unfortunately anticipate that the virus will continue to impact individuals, health systems and economies for some time. We remain hopeful, however, that the pandemic will have sufficiently subsided to enable the global diabetes community to convene safely in Bangkok.

In the current context, it is important to remember we are facing an ever-increasing global epidemic of diabetes. The Western Pacific region is among the regions most impacted. It is home to one in three of all people living with diabetes, more than half of which are undiagnosed. The numbers continue to increase, yet the resources allocated to detecting, treating and preventing diabetes and its complications lag way behind the growing demand. The current COVID-19 pandemic will likely place the resources that do exist under additional strain.

With this in mind, the IDF Congress 2021 in Bangkok provides the ideal forum for the global diabetes community to continue to make the case for the level of attention, recognition and resources that diabetes deserves. The Congress will convene at the end of a year of activities to mark the centenary of the discovery of insulin. It is therefore an opportunity to not only to celebrate a historic therapeutic advancement that changed the lives for so many, but also to advocate for the millions of people with diabetes that continue to experience difficulty accessing the essential medications, technologies and care they need.

IDF 2021 in Bangkok will provide a unique forum for knowledge exchange, bringing together the extensive global network of physicians, scientists, nurses, educators, other healthcare professionals, government officials, policy makers, media and diabetes associations that IDF represents. The Congress will harness the latest technologies to ensure a safe and dynamic experience for all delegates and help foster the collaborations, connections and political actions required to place diabetes at the top of the global health agenda and improve the lives of people living with diabetes and those at risk.

I look forward to welcoming you in Bangkok to shape the future of diabetes through our strong and united global voice.

Prof. Andrew Boulton
President, International Diabetes Federation
On behalf of the National and Programme Committee, we are delighted to welcome you to Bangkok, capital city of the Kingdom of Thailand, the land of smiles and one of the most vibrant business destinations with a rich cultural heritage.

The Bangkok International Trade and Exhibition Center (BITEC) is a superb meeting venue with fully equipped facilities, within convenient reach by BTS sky-train. It is a perfect place for colleagues from around the world to meet and greet, update scientific knowledge, share new data and innovations and exchange experiences.

Welcome to Bangkok

The scientific programme will cover a wide range of topics relevant to diabetes. Across eight parallel streams, it will address the basic science and biology of diabetes, the development and application of new drugs, therapies and technologies, the latest information from clinical trials, the burden of diabetes and its complications in populations around the globe, the prevention of diabetes, and policy and advocacy issues critical to addressing the diabetes pandemic.

A particular focus on issues relating to women and to the voice of people with diabetes will be a feature of the programme. Speakers will include world-leading experts, early career researchers, and people at the coalface who work with or live with diabetes. A range of different formats from lectures to debates and workshops will present cutting-edge findings and state-of-the-art reviews. The highly interactive environment will encourage exchanges of views and the development of new ideas and collaborations.

We take great pride in the Thai uniqueness, their legendary hospitality and the friendliness of the Thai people and we look forward to welcoming you all to an inspiring and memorable IDF Congress.

Wannee Nitiyanant, M.D.  
Chair, National Advisory Committee

Professor Jonathan Shaw  
Chair, Programme Committee
WHY ATTEND THE IDF CONGRESS 2021?

Learn
- 120 hours of scientific sessions and satellite symposia
- Over 1000 posters
- 20 CME credits to advance your learning

Discover
- Cutting-edge science
- 8 programme streams
- International exhibitors

Connect
- 250 international speakers
- 7,000 delegates
- 240 IDF members
# CONGRESS COMMITTEES

## National Advisory Committee

- Wannee Nitiyanant  
  Thailand  
  Chair

## Programme Committee

| Chair       | Jonathan Shaw  
             | Australia       |
|-------------|----------------|
| Vice Chair  | Joao Manuel Valente Nabais  
             | Portugal        |
| Streams     | Basic and Translational Science (BTS) |
| Stream Lead | Paula Macedo  
             | Portugal        |
| Stream Member | Young-Bum Kim  
                | USA             |
| Stream Member | Norbert Stefan  
                 | Germany         |
| Stream Member | Sung Hee Choi  
                 | South Korea     |
| Streams     | Clinical, Therapeutic and Technology Research (CTT) |
| Stream Lead | Shashank Joshi  
             | India           |
| Stream Member | David Klonoff  
                | USA             |
| Stream Member | Chantal Mathieu  
                 | Belgium         |
| Stream Member | Pablo Aschner Monotoya  
                  | Columbia        |
| Streams     | Diabetes Complications and Comorbidities (DCC) |
| Stream Lead | Andrea Luk  
             | China           |
| Stream Member | Kamlesh Khunti  
                | United Kingdom  |
| Stream Member | David Preiss  
                 | United Kingdom  |
| Streams     | Health Services and Policy (HSP) |
| Stream Lead | Niti Pall  
             | United Kingdom  |
| Stream Member | Partha Kar  
                | United Kingdom  |
| Stream Member | Cajsa Lindberg  
                 | Sweden          |
| Stream Member | Reem Fahd Al Bunyan  
<pre><code>             | Kingdom of Saudi Arabia |
</code></pre>
<table>
<thead>
<tr>
<th>Stream</th>
<th>Lead</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic and Translational Science (BTS)</td>
<td>Paula Macedo</td>
<td>Maria Inês Schmidt, Zilin Sun, Shashank Joshi</td>
</tr>
<tr>
<td>Clinical, Therapeutic and Technology Research (CTT)</td>
<td>Joao Manuel Valente Nabais</td>
<td>Kamlesh Khunti, Partha Kar, Usha Siriam</td>
</tr>
<tr>
<td>Diabetes Complications and Comorbidities (DCC)</td>
<td>Andrea Luk</td>
<td>Sana Ajmal, Ayesha Motala, Niti Pall</td>
</tr>
<tr>
<td>Health Services and Policy (HSP)</td>
<td>Shashank Joshi</td>
<td>Maria Inês Schmidt, Zilin Sun, Shashank Joshi</td>
</tr>
<tr>
<td>Diabetes in Women (DIW)</td>
<td>Paula Macedo</td>
<td>Maria Inês Schmidt, Zilin Sun, Shashank Joshi</td>
</tr>
<tr>
<td>Education and Integrated Care (EIC)</td>
<td>Paul Macedo</td>
<td>Maria Inês Schmidt, Zilin Sun, Shashank Joshi</td>
</tr>
<tr>
<td>Epidemiology and Public Health (EPH)</td>
<td>Paul Macedo</td>
<td>Maria Inês Schmidt, Zilin Sun, Shashank Joshi</td>
</tr>
<tr>
<td>Living with Diabetes (LWD)</td>
<td>Paul Macedo</td>
<td>Maria Inês Schmidt, Zilin Sun, Shashank Joshi</td>
</tr>
</tbody>
</table>
KEY DATES

Registration
- 1 February 2021 – online registration opens
- 30 June 2021 – Early rate deadline

Abstracts
- 14 April 2021 - Abstract submission opens
- 19 June 2021 - Abstract submission closes

Scientific programme
- June 2021 - Fully searchable scientific programme online
- November 2021 - Congress app goes live
### Abstracts
- 14 April 2021 - Abstract submission opens
- 19 June 2021 - Abstract submission closes

### Congress-at-a-Glance

<table>
<thead>
<tr>
<th>Monday 6 Dec</th>
<th>Tuesday 7 Dec</th>
<th>Wednesday 8 Dec</th>
<th>Thursday 9 Dec</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>10.00</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>10.30</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>12.00</td>
<td>Satellite Symposia</td>
<td>Exhibition</td>
<td>Exhibition</td>
</tr>
<tr>
<td>12.30</td>
<td>Posters</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>13.30</td>
<td>Satellite Symposia</td>
<td>Exhibition</td>
<td>Exhibition</td>
</tr>
<tr>
<td>14.00</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>15.30</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>15.45</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>16.30</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>17.00</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>17.30</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>18.00</td>
<td>Opening &amp; Welcome Reception</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>19.30</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Farewell Evening</td>
</tr>
<tr>
<td>20.00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## OPENING HOURS

<table>
<thead>
<tr>
<th>Activity</th>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual registrations</td>
<td>Monday 6 December</td>
<td>07.00-18.00</td>
</tr>
<tr>
<td></td>
<td>Tuesday 7 – Thursday 9 December</td>
<td>07.00-18.00</td>
</tr>
<tr>
<td>Opening &amp; welcome reception</td>
<td>Monday 6 December</td>
<td>18.00-20.00</td>
</tr>
<tr>
<td>Exhibition</td>
<td>Tuesday 7 - Thursday 9 December</td>
<td>10.00-17.00</td>
</tr>
<tr>
<td>Global Village</td>
<td>Tuesday 7 - Thursday 9 December</td>
<td>10.00-17.00</td>
</tr>
<tr>
<td>Posters</td>
<td>Tuesday 7 - Thursday 9 December</td>
<td>10.00-17.00</td>
</tr>
<tr>
<td>Programme sessions</td>
<td>Tuesday 7 - Thursday 9 December</td>
<td>08.30-16.30</td>
</tr>
<tr>
<td>e-poster discussions</td>
<td>Tuesday 7 - Thursday 9 December</td>
<td>12.30-13.30</td>
</tr>
<tr>
<td>Diabetes Spotlight</td>
<td>Tuesday 7 - Thursday 9 December</td>
<td>10.00-16.30</td>
</tr>
<tr>
<td>Satellite symposia</td>
<td>Monday 6 December</td>
<td>08.30-16.30</td>
</tr>
<tr>
<td></td>
<td>Tuesday 7 – Thursday 9 December</td>
<td>12.30-13.30</td>
</tr>
<tr>
<td></td>
<td>Tuesday 7 – Thursday 9 December</td>
<td>17.30-19.30</td>
</tr>
</tbody>
</table>
Chair: Jonathan Shaw, Australia

Jonathan Shaw MD, FRCP (UK), FRACP, FAAHMS is Deputy Director at Melbourne’s Baker Heart and Diabetes Institute. He is also an endocrinologist, Chair of the Diabetes Advisory Group to the Australian Institute of Health and Welfare (AIHW), Council Member of the Australian Diabetes Society, and Past-President of the International Diabetes Epidemiology Group. His awards include the International Diabetes Epidemiology Group (IDEG) Peter Bennett award (2011), the Australian Diabetes Society (ADS) Jeff Flack Diabetes Data award (2015), and the ADS Kellion Diabetes award (2018). He has authored more than 400 peer-reviewed scientific papers and 35 book chapters, and was included in the Thomson Reuters The World’s Most Influential Scientific Minds (2014), and the Clarivate Analytics list of the world’s most Highly Cited Researchers (2017 and 2018). His areas of interest include epidemiology and clinical trials in diabetes.

Vice Chair: João Valente Nabais, Portugal

João Valente Nabais PhD is Assistant Professor with Habilitation at University of Evora (Portugal). Diagnosed with type 1 diabetes in 1981, João has been actively involved in the field of diabetes through his work at national and international level. He has been involved in diabetes camps and the development of education courses for people with diabetes and parents of children with diabetes, and oversaw the launch of the IDF Europe Youth Leadership Camp. João is a member of the Comprehensive Health Research Center and a consultant to the Portuguese Diabetes Association (APDP). He is a Past President of the IDF European Region (2012-15) and currently a Vice-President of IDF. He has published 60 papers in international journals, participated in 15 R&D projects as Researcher and is the co-author of 3 patents.

Basic and Translational Science Stream Lead: Paula Macedo, Portugal

Paula Macedo is currently Professor at the NOVA Medical School, NOVA University in Lisbon, and at the Department of Medical Sciences Universidade Aveiro, Portugal. Professor Macedo graduated in Pharmacy from the Faculty of Pharmacy at the University of Lisbon and obtained her PhD from the Department of Pharmacology and Therapeutics at the University of Manitoba, Canada. She is the principal investigator of the MEDIR group based at CEDOC NOVA Medical School.

Professor Macedo has been awarded several grants as a principal investigator on her preferred research subjects in both basic and clinical research. She has been working in research areas related to hepatic vasculature and hepatic control of insulin sensitivity. Significant contributions include the description and explanation of meal-induced insulin action sensitization in prediabetes and in diabetes-related pathologies. Lately, her interests are focused on the impact of the subclinical impairments of the autonomic nervous system on glucose and lipid metabolism and in the genetics and environmental factors controlling insulin clearance and insulin resistance at the prediabetes stage, focusing on the gut-liver axis.
Diabetes Complications and Comorbidities Stream Lead: Andrea Luk

Andrea Luk is currently the Associate Professor of the Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. She is also the Medical Director (Non-Oncology) of the Phase 1 Clinical Trial Centre and serves as an honorary associate consultant at the Prince of Wales Hospital. Dr Luk completed her specialist training in endocrinology, reproduction and metabolism in 2007. Her research interests include epidemiology of diabetes and diabetes-related complications, study of the aetiology and mechanisms of young-onset diabetes, as well as translational studies of care models in people with diabetes.

Diabetes in Women Stream Lead: Maria Inês Schmidt

Maria Inês Schmidt MD, PhD is an endocrinologist and epidemiologist trained at the John Hopkins Hospital and at the University of North Carolina. Professor at the School of Medicine of the Federal University of Rio Grande do Sul, Brazil where she teaches medical students and graduate students in epidemiology. Her main research focus is on the epidemiology of type 2 diabetes, obesity, gestational diabetes, and diabetes prevention in women. Current main projects include: LINDA Brasil, a randomized controlled trial for the prevention of diabetes in women with recent gestational diabetes; ELSA-Brasil, a cohort study of 15105 Brazilian adults now followed-up for 10 years; Surveillance of diabetes and its complications in Brazil; and the Global Burden of Disease (GBD) project. Over the years, she has contributed to the development of IDF guidelines and acted as a panel member of various WHO consultations related to diabetes. She is a member of the Lancet Commission on Diabetes.

Education and Integrated Care Stream Lead: Zilin Sun

Zilin Sun M.D., Ph.D., is Professor of Medicine and the Director of the Institute of Diabetes in Southeast University in Nanjing, China. Dr. Sun received his doctoral trainings in Clinical Pharmacology and Clinical Medicine from China Pharmaceutical University and Ulm University in Germany. He is now Chairman of the Chinese Association of Diabetes and Microcirculation and a Committee Member of the Chinese Society of Endocrinology. He was also the former Vice Director of the Diabetes Education and Management Group of the Chinese Diabetes Society, the former Committee member of Chinese Diabetes Society, and the former Chairman of the Jiangsu Diabetes Society. Dr. Sun is also on the editorial board of “BMC Med” and “Diabetes Metab J” and has published more than 200 scientific papers, including more than 100 SCI-indexed publications.

Epidemiology and Public Health Stream Lead: Ayesha Motala

Ayesha Motala is a specialist physician and currently Professor and Clinical Head in the Department of Diabetes and Endocrinology at Inkosi Albert Luthuli Central Hospital affiliated to the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Ayesha is a clinician and her research has focussed on the epidemiology, genetic and clinical aspects of diabetes and other non-communicable diseases (NCDs). She has been involved in several large-scale population studies, both cross-sectional and longitudinal, on the epidemiology of diabetes in African (black) and Asian Indian communities in KwaZulu Natal, both urban and rural. She is the lead principal investigator of a large consortium-wide study at 10 sites across 7 countries in sub-Saharan Africa - the Human Hereditary and Health in Africa (H3Africa) study on diabetes, funded through the Wellcome Trust.
**Living with Diabetes Stream Lead: Sana Ajmal**

Sana Ajmal is a seasoned diabetes advocate, with years of experience with various IDF programmes and activities, including Young Leaders in Diabetes, Diabetes Education Consultative Section, the World Diabetes Congress Program Committee and other international bodies. She is the Founder and Executive Director of Meethi Zindagi, which is the only national, people-centric, non-profit organization in Pakistan, providing psycho-social support, peer education and medicines to the diabetes community and empowering them to lead thriving lives. Her distinction lies in tailoring international best practices to a local perspective and simplifying complex solutions with an engineered approach and technology to create robust systems and services in resource limited settings.

**Clinical, Therapeutic and Technology Research Stream Lead: Shashank Joshi**

Shashank R. Joshi is the Chair of the Southeast Asian Region of IDF and Dean of the Indian College of Physicians from Mumbai, India. He is Past President of the Endocrine Society of India, RSSDI and many other societies in India and Asia. He is a well-known Endocrinologist attached to Joshi Clinic and Lilavati Hospital and has published more than 800 publications and written 100 books. His areas of interest includes diabetes, diabetes therapy and obesity apart from developing low cost interventions for the developing world.

**Health Services and Policy Stream Lead: Niti Pall**

Niti Pall is President of IDF Europe. She is Global Medical Director for KPMG and Senior Mobile Health Advisor for AXA. She also sits on the board of the Birmingham Women’s and Children’s Hospital. Niti is a senior Doctor who has deep expertise in primary care models and health benefit management across the world. Niti helped to build up the largest chain of primary care clinics in the UK – the Modality Partnership – and held several senior commissioning roles in the English NHS. She has innovated with new extended primary care and enhanced primary care including diabetes care across the world. Her interest in diabetes spans three decades as her son has had Type 1 diabetes for 27 years, she has worked in diabetes advocacy since his first diagnosis and is passionate about involving patients in driving good quality services. She established a chain of primary care clinics in India. She was Medical and Innovation Director of Emerging Markets for BUPA, where she helped to create an innovative model of micro-insurance in Bangladesh in partnership with Telenor. She established and supervised clinics in China, Saudi Arabia, Poland and Hong Kong and helped create health benefit management systems in Saudi Arabia, UK, India, Hong Kong, and Thailand. She has delivered universal healthcare work in India, Middle east Kazakhstan, Philippines, Sri Lanka and Indonesia. She is working with 8 AXA countries developing mobile health propositions that include new funding products for emerging customers. This has included digital new technologies for diabetes care at an affordable cost. Affordable healthcare remains a passion and an interest.
LEARNING OBJECTIVES

Basic and Translational Science (BTS)

Stream Description
This stream addresses recent progress in diabetes research and its future applications in diabetes care as well as the latest advances in science-based clinical practice.

Learning Objectives
After attending the sessions in the Basic and Translational Science stream, the participant will be:
• Updated on advances in the multifactorial nature of diabetes
• Exposed to newly proposed mechanisms underlying diabetes establishment and progression
• Aware of innovative approaches for the study of diabetogenic determinants
• Alerted to novel pathophysiological mechanisms of diabetes comorbidities
• Informed about potential impacts of research in prevention and improved treatment of diabetes

Clinical, Therapeutic and Technology Research (CTT)

Stream Description
This stream deals with current and future areas of clinical therapeutics, diabetes technology and future research direction.

Learning Objectives
After attending the sessions in the Clinical, Therapeutic and Technology Research stream, the participant will be able to:
• Understand the evidence base for current and emerging treatments of diabetes
• Discuss treatment pathways and individual agents with respect to outcomes as well cost effectiveness
• Understand insulin in the past 100 years, as well as the present and future

• Understand closed loop systems, time in range, the artificial pancreas, telehealth and virtual protocols for diabetes management
• Understand access, affordability and adherence in resource limited settings, and clinical practice recommendations

Diabetes Complications and Comorbidities (DCC)

Stream Description
This stream provides updates on the latest research in basic and clinical science of diabetes complications and comorbidities.

Learning Objectives
After attending the sessions in the Diabetes Complications and Comorbidities stream, the participant will be able to:
• Understand the latest research in the pathophysiology of diabetes complications
• Identify risk factors for diabetes complications and approaches for early detection and timely intervention of these conditions
• Apply evidence-based medicine in prevention and clinical management of diabetes complications
• Recognise the impact of diabetes on the development and prognosis of a wide range of non-vascular complications

Diabetes in Women (DIW)

Stream Description
This stream will focus on the best evidence to treat and prevent diabetes and related conditions among women, including hyperglycaemia in pregnancy (HIP) and its long-term effects on mother and child.

Learning Objectives
After attending the sessions in the Diabetes in Women stream, the participant will be able to:
• Use current best evidence to inform health policy and clinical
decision making for diabetes in women.
• Understand that HIP is a common condition associated with higher incidence of maternal mortality, maternal morbidity, perinatal and neonatal morbidity and long term consequences for both mother and child.
• Use pregnancy as a window of opportunity to improve health throughout the life-course and prevent intergenerational transmission of non-communicable disease

**Education and Integrated Care (EIC)**

**Stream Description**
This stream focuses on all aspects related to diabetes education and diabetes self-management and support, with a particular interest on diabetes care delivered by healthcare providers, peers, families, or communities, as well as on diabetes management systems/models integrated with tools dealing with diabetes detection, glucose monitoring, diet, or physical activity.

**Learning Objectives**
After attending the sessions in the Education and Integrated Care stream, the participant will be able to:
• Address a variety of challenges in diabetes education and diabetes self-management and support, as well as the possible coping strategies
• Teach people how to live with diabetes and guide educators/healthcare providers on how to manage diabetes by cooperating with peers, families, or communities
• Optimize the design of training courses on diabetes education or care with focuses on diabetes detection, complication screening, and the use of tools
• Establish novel models on diabetes self-management and support by making use of tools that may help to enhance self-efficacy and improve clinical-related outcomes
• Better understand the benefits of dietary and/or physical activity interventions on diabetes management and control

**Epidemiology and Public Health (EPH)**

**Stream Description**
This stream deals with updates on recent research and advances on the epidemiology of diabetes diagnosis, complications and prevention, the public health challenges being faced and how to prevent and deal with them.

**Learning Objectives**
After attending the sessions in the Epidemiology and Public Health stream the participant will be able to:
• Understand the importance of rigorous methodology when undertaking epidemiology studies
• Recognise the gaps in epidemiology research that need to be filled
• Understand how to overcome current and emerging challenges to metabolic health
• Describe how current epidemiological data can be used to help shape future policy and healthcare implementation
• Translate successful strategies from projects presented into future prevention and management programmes

**Health Services and Policy (HSP)**

**Stream Description**
This stream will focus on health systems and policies that affect diabetes care, and most importantly people living with diabetes. There will be a focus on both the wider funding of healthcare in general, and on policies that impact diabetes care at a micro and macro level.

**Learning Objectives**
After attending the sessions in the Service and Policy stream, the participant will be able to:
• Learn about trends at a governmental level on funding mechanisms
• Understand how policies affect diabetes care
• Understand how the most effective health systems deal with funding and provision challenges
• Learn about innovative policies that lead to better diabetes care
• Hear about how people with diabetes contribute to effective policy making and influence

**Living with Diabetes (LWD)**

**Stream Description**
The stream gives an in-depth insight into the perspectives of people living with diabetes and highlights their role in diabetes awareness, prevention, education, support, advocacy and communication.

**Learning Objectives**
After attending the sessions in the Living with Diabetes stream, the participant will be able to:
• Recognise the multiple aspects of living the best life possible with diabetes
• Understand some of the day-to-day challenges faced by people with diabetes
• Understand the impact of various support systems and approaches on the lives of people with diabetes
• Identify technologies and approaches with potential for a positive impact on diabetes management
• Identify and analyse barriers and enablers to empowerment and positive self-care
CALL FOR ABSTRACTS

The IDF Congress 2021 welcomes original abstracts on subjects relevant to the following streams:

- Basic and Translational Science (BTS)
- Clinical, Therapeutic and Technology Research (CTT)
- Diabetes Complications and Comorbidities (DCC)
- Diabetes in Women (DIW)
- Education and Integrated Care (EIC)
- Epidemiology and Public Health (EPH)
- Health Services and Policy (HSP)
- Living with Diabetes (LWD)

Abstract submission Guidelines

Online abstract submission is open from 14 April to 19 June 2021.

- **Submission mode:** Abstract submission is only possible online on the IDF Congress 2021 website. Abstracts submitted by post, fax or email will NOT be accepted. The online abstract submission module will NOT be available after 19 June 2021.
- **IDF congress profile:** In order to submit an abstract, a congress profile must be created giving access to the online abstract submission module. The submitting author must ensure accurate contact details are entered. One or more abstracts can be submitted by logging into this congress profile.
- **Submitting author / presenting author:** If the submitting author is not also the presenting author, the submitting author is responsible for informing the presenting author of all communications received regarding the abstract.
- **Presenting author registration:** The presenting author must be registered by 31 August 2021. If the presenting author is not registered by this date, their abstract will be REMOVED from the programme.
- **Number of submissions:** There can only be ONE presenting author per abstract. The same abstract CANNOT be submitted multiple times by listing different presenting authors. An unlimited number of abstracts can be submitted by an author.
- **Language:** All abstracts must be submitted in English. Should English not be your first language, you may wish to have your abstract examined by a native English speaker prior to submission.
- **Accuracy of content:** Submitted abstracts may be edited online up to the abstract submission deadline of 19 June 2021. Abstracts CANNOT be edited or revised in any way after the deadline. All accepted abstracts will be published as submitted by the authors. The responsibility for the submission of an accurate and precise abstract lies solely with the authors.
- **Originality of abstracts:** Work published in peer-reviewed journals before 6 December 2021 should NOT be submitted to the IDF Congress 2021. Abstracts already presented at face-to-face meetings should also not be submitted. However, previously submitted work can be resubmitted provided there are new methods and/or findings.
- **Disclosure of interests:** Any financial relationships with commercial entities related to the authors or products and processes described in the work must be correctly disclosed.
- **Regulatory approval:** The submitting author confirms that local regulatory approval has been obtained as required by local laws.
- **Author consent:** The submitting author declares all authors have read and approved the submitted work.
- **Copyright transfer:** Authors must attest that their submitted work does not infringe any copyright legislation. Copyright for the publication of abstracts is automatically transferred to the International Diabetes Federation upon submission and acceptance of the regulations within the online submission module. For rejected abstracts, the copyright reverts back to the authors.

Instructions

- **Topic:** There are various categories that have been defined for the abstract programme within the eight streams. Ensure that you select the MOST relevant topic and stream which BEST describes the content of your abstract. Categories are used for reviewing and indexing purposes.
- **Abstract title:** The title is limited to 120 characters including spaces and should be brief and relevant. Special characters should
NOT be used in your title but spelt out instead (e.g. α should be written as alpha, β as beta). Only use standard abbreviations and generic drug names in the title.

- **Authors:** Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.

- **Abstract body:**
  - The abstract *structure* is laid out under the headings Background, Aims, Method, Results and Discussion.
  - *Font size and style* will be automatically configured by the system.
  - *Tables* will be accepted in the submission field and count towards the character limit. The character deduction for tables is not fixed and will be generated by the character count shown below the submission field. Graphs, figures and photographs are NOT allowed.
  - The *length* of the abstract is limited to 500 words. Only the abstract body and any inserted tables count towards this word limit. The word count displayed beneath the submission field is final and indisputable.
  - Only commonly accepted *abbreviations* should be used (e.g. GDM, BMI, DM). Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).
  - Only approved and generic (non-proprietary) *drug names* should be used.
  - Do NOT enter the title, authors, or grant information into the abstract body but include any *references* at the end of the abstract.

**Selection and notification process**

- **Selection:** All submitted abstracts undergo a peer-review process by an international panel of reviewers. Accepted abstracts are selected for oral presentation within the main programme (10 min plus 5 min discussion), e-poster presentations during lunch break (5 min) or poster display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.

- **Notification:** Notice of acceptance or rejection of submitted abstracts will be sent to the submitting authors by 6 August 2021. It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of the abstract.

- **Author Registration:** Presenting authors of accepted abstracts MUST register for the congress by 31 August 2021. If the entire registration fee is not paid by the deadline, the abstract will be automatically withdrawn and will NOT be presented or published.

- **Late-breaking abstract policy:** The IDF Congress 2021 will not be accepting late-breaking abstracts. All abstracts must be submitted during the regular submission period starting on 14 April and ending on 19 June 2021.

**Abstract Categories**

- Bariatric surgery
- Blood pressure
- Care delivery
- Cognition, psychology and behaviour
- Comorbidities
- Complications
- Complications - cardiovascular disease
- Complications - eye
- Complications - foot
- Complications - kidney
- Complications - nerve
- Complimentary medicine
- Diabetes advocacy
- Diabetes and infections
- Diabetes and the brain
- Diabetes organisations
- Diabetes education
- Diabetes epidemiology
• Diabetes in childhood and adolescence
• Diabetes in Indigenous groups
• Diabetes in migrant populations
• Diabetes in rural areas
• Diabetes in the elderly
• Diabetes management
• Diagnosis and classification
• Discrimination and diabetes
• Environment and lifestyles
• Epigenetics
• Genetics of diabetes
• Glucagon
• Guidelines, clinical care
• Health professional education and development
• Health services research
• Health workforce
• Healthcare financing
• Hypoglycaemia
• In utero environment
• Incretin physiology and pathophysiology
• Incretin therapies
• Inflammation
• Insulin action
• Insulin secretion, beta-cell function
• Insulin therapy and devices
• Islets - beta-cell biology
• Lipids and lipoproteins
• Living with diabetes
• Microbial flora
• Nutrition and diet
• Obesity
• Oral glucose-lowering therapies
• Patient engagement
• Physical activity
• Pregnancy and gestational diabetes
• Primary and secondary prevention
• Rights and responsibilities of people with diabetes
• Screening and risk stratification
• Stem cell therapy
• Technology
• Telecommunication, internet and social media
• Transplantation - islet and pancreas
• Type 1 diabetes
• Type 2 diabetes

Continuing Medical Education (CME)

Applications for Continuing Medical Education (CME) accreditation for physicians and other healthcare professionals will be presented to the national accreditation body and the European Accreditation Council for Continuing Medical Education (EACCME). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). It is expected that the IDF Congress 2021 will be accredited with approximately 20 hours of CME credits. CME certificates will be available after the congress.
REGISTRATION

Individual Registration

- Online registration opens on 1 February 2021 on the IDF Congress 2021 website. A valid email address will be required.
- Registration will be possible during the congress (6 - 9 December 2021).
- Day rates will also be available onsite.

Registration opening hours

<table>
<thead>
<tr>
<th>Days</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday 6 - Thursday 9 December</td>
<td>07.00 – 18.00</td>
</tr>
</tbody>
</table>

IDF Congress 2021 Registration rates
(all indicated amounts are in EUR)

<table>
<thead>
<tr>
<th>Category</th>
<th>ONSITE attendee</th>
<th>ONLINE attendee</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Early rate 1 Feb - 30 June</td>
<td>Standard rate 1 Jul – 9 Dec</td>
</tr>
<tr>
<td>Regular rate (Medical Doctor)</td>
<td>500</td>
<td>600</td>
</tr>
<tr>
<td>Reduced rate (Healthcare Professionals)</td>
<td>300</td>
<td>400</td>
</tr>
<tr>
<td>Student rate (1)</td>
<td>75</td>
<td>75</td>
</tr>
<tr>
<td>Low and lower-middle income economies LMIE AND Thailand (2)</td>
<td>200</td>
<td>300</td>
</tr>
</tbody>
</table>

(1) for participants who are students at the time of the congress. Not applicable to post doctorate students. (2) for participants who are citizens AND residents of a low and lower-middle income economy as per World Bank definition and Thailand.

The registration fee for onsite attendees includes entry to all congress sessions, the exhibition and poster area, the opening, a daily lunch and a congress bag containing congress material. All congress materials will be distributed on site.

The registration fee for online attendees includes access to all poster sessions and presentation, selected live streamed sessions, virtual exhibition and digital congress material. All congress content will be available to all registered attendees for view on demand after the congress for a duration of four weeks.
Group Registration

- Group registration is available for groups of at least 10 participants. Group discounts are available as of 30 participants. One contact person should coordinate with the Congress Secretariat.
- The group rate is at the regular rate per person.
- All registration information will be sent to the group contact person, who will then be responsible for distribution to the group.
- The group contact person will collect the group’s registration badges on Sunday 5 December 2021.

Payment

Payment should preferably be made by credit card (Eurocard/Mastercard, VISA or American Express). Please indicate the card owner’s name (as shown on the card) and the expiry date.
Payments can also be done by direct bank transfer without charges to the beneficiary:
- Beneficiary name: IDF
- Account name: IDF Congress
- Account number / IBAN: BE67 6451 4103 3587
- Swift code / Routing / BIC: JVBABE 22
- Bank name: Bank J. Van Breda & Co
- Bank address: Vlaanderenstraat 53, 9000 Gent, Belgium.

The name and address of the participant should be clearly stated on the bank transfer.
Please bear in mind that an international bank transfer can take up to 10 days to reach our account.
If payment is not received by the corresponding deadline (early or standard registration), the subsequent rate will automatically apply.

Please note that after 13 November 2021 only credit card payment will be possible.

Name change/cancellation for individual registrants

All name changes and cancellation requests must be done in writing by email. No changes or cancellations will be accepted by telephone. Name change for a confirmed registration will be subject to an administrative fee of 50 EUR per participant.
Cancellation of a confirmed registration will be subject to an administrative fee of 50 EUR per participant. As of 13 November 2021, no refund will be possible.

Refunds

Any applicable refund will be reimbursed after the congress.
**ACCOMMODATION, TRAVEL AND VISA**

**Accommodation**

ICS International Conference Services is the exclusive and officially appointed housing bureau for the IDF Congress 2021 and will offer assistance with the coordination of housing requests. A wide variety of hotels across all categories and budgets have been secured in Bangkok to meet our delegates needs. Congress hotels are well connected to the BITEC Congress Center and within easy reach of the congress venue.

IDF Congress 2021 Housing Bureau

![ICS Logo]

**Džiuginta Tyriūtė**  
Housing Manager  
T: +1 604 681 2153 ext. 131  
E: IDF2021-grouphousing@icsevents.com  
www.ICSEvents.com

**Unofficial agencies**

There are companies that claim to offer housing & registration services for the IDF Congress, which are not affiliated with IDF and do not offer any services on our behalf.

All sponsors, exhibitors and delegates are encouraged to book at the official IDF Congress 2021 hotels and through the official IDF Congress 2021 housing agency to benefit from special rates.

IDF cannot be held responsible for any losses incurred as a result of bookings made through unofficial websites.
Chit Lom Station
Holiday Inn Bangkok Phloen Chit, 4*
Courtyard by Marriott Bangkok, 4*
Renaissance Bangkok Rachaprasong Marriot, 5*

Siam Station
Novotel Bangkok on Siam Square, 4*

Ploen Chit Station
JW Marriott Bangkok, 5*
Novotel Bangkok Ploenchit Sukhumvit Hotel, 4*

Nana Station
Mercure Bangkok Sukhumvit 11, 4*
Aloft Bangkok Sukhumvit 11

National Stadium
Mercure Bangkok Siam Hotel, 4*

Asok Station
Four Points Sheraton Bangkok, 4*
Sheraton Grand Sukhumvit, 5*
Novotel Bangkok Sukhumvit, 4*

Phrom Phong
BKK Marriott Marquis Queen’s Park, 5*
Holiday Inn Bangkok Sukhumvit, 4*
Mercure Bangkok Sukhumvit 24, 4*

Thong Lor
Bangkok Marriott Hotel Sukhumvit, 5*

On Nut Station
X2 Vibe Bangkok Sukhumvit, 4*
## Hotel Options

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Distance from BITEC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Driving</td>
</tr>
<tr>
<td><strong>5 star hotels</strong></td>
<td></td>
</tr>
<tr>
<td>Bangkok Marriott Marquis Queen’s Park</td>
<td>20-40 min drive</td>
</tr>
<tr>
<td>Bangkok Marriott Hotel Sukhumvit</td>
<td>24-40 min drive</td>
</tr>
<tr>
<td>JW Marriott Bangkok</td>
<td>24-40 min drive</td>
</tr>
<tr>
<td>Renaissance Bangkok Rachaprasong</td>
<td>30-45 min drive</td>
</tr>
<tr>
<td>Sheraton Grande Sukhumvit</td>
<td>20-50 min drive</td>
</tr>
<tr>
<td><strong>4 star hotels</strong></td>
<td></td>
</tr>
<tr>
<td>Aloft Bangkok Sukhumvit 11</td>
<td>25-45 min drive</td>
</tr>
<tr>
<td>Courtyard by Marriott Bangkok</td>
<td>30-50 min drive</td>
</tr>
<tr>
<td>Four Points Sheraton Bangkok</td>
<td>25-45 min drive</td>
</tr>
<tr>
<td>Holiday Inn Bangkok Phloen Chit Road</td>
<td>20-45 min drive</td>
</tr>
<tr>
<td>Holiday Inn Bangkok Sukhumvit</td>
<td>22-50 min drive</td>
</tr>
<tr>
<td>Mercure Bangkok Sukhumvit 11</td>
<td>14-45 min drive</td>
</tr>
<tr>
<td>Mercure Bangkok Sukhumvit 24</td>
<td>20-40 min drive</td>
</tr>
<tr>
<td>Mercure Bangkok Siam Hotel</td>
<td>30-50 min drive</td>
</tr>
<tr>
<td>Novotel Bangkok Ploenchit Sukhumvit Hotel</td>
<td>18-20 min drive</td>
</tr>
</tbody>
</table>
## Hotel

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Distance from BITEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novotel Bangkok Sukhumvit 20</td>
<td>30-50 min drive</td>
</tr>
<tr>
<td>Novotel Bangkok on Siam Square</td>
<td>18-20 min drive</td>
</tr>
<tr>
<td>X2 Vibe Bangkok Sukhumvit</td>
<td>15-35 min drive</td>
</tr>
</tbody>
</table>

### 4 star hotels

**Novotel Bangkok Sukhumvit 20**
- Drive: 30-50 min
- Public Transit: 45 min via skytrain (Asok station)

**Novotel Bangkok on Siam Square**
- Drive: 18-20 min
- Public Transit: 45 min via skytrain (Siam station)

**X2 Vibe Bangkok Sukhumvit**
- Drive: 15-35 min
- Public Transit: 30 min via skytrain (On Nut station)

---

## Travel

Bangkok’s modern Suvarnabhumi International Airport is one of the world’s top airports, welcoming more than 45 million passengers annually. It is served by at least 80 international airlines linking 170 cities around the globe. IDF appointed ATPI Travel as the official travel agency for the IDF Congress 2021.

Highly experienced travel consultants have been assigned to IDF to accommodate all IDF travel needs before, during and after the congress. ATPI travel consultants and an assigned Account Manager will be responsible to assist our congress delegates with their travel needs. ATPI will offer an online booking form providing everything needed to plan, book and manage your travel in one easy-to-use online platform.

---

## Visa

Thailand is a visa-friendly country. Delegates from 58 countries and Hong Kong SAR are automatically granted permission to stay for 30 days in the country. Delegates from an additional 19 countries can apply for a “Visa on Arrival” at the Immigration Hall in all Thai international airports. For citizens not covered by the above, visas can be obtained from the nearest Royal Thai Embassy or Consulate.

For more information please visit [www.mfa.go.th](http://www.mfa.go.th) and check Consular Services – Thailand Visa Information.

---

**ATPI Travel**

Mily Vlachou
Bellina Bardaka
T: +30 210 9231100
E: IDF-Bangkok2021@atpi.com
www.atpi.com
CONTACT

All enquiries and correspondence in relation to the congress should be directed to:

**International Diabetes Federation**  
Avenue Herrmann-Debroux 54  
1160 Brussels  
Belgium  
[www.idf.org/congress](http://www.idf.org/congress)

**General enquiries**  
congress@idf.org

**Registration**  
registration@idf.org

**Industry relations**  
industry@idf.org

**Programme and abstracts**  
programme@idf.org

**Housing**  
IDF2021-grouphousing@icsevents.com

**Media**  
media@idf.org

**Join the conversation!**  
Find us on Facebook & Twitter  
[www.facebook.com/intdiabetesfed](http://www.facebook.com/intdiabetesfed)  
@IntDiabetesFed  
#IDF2021

---

26
DIABETES: NURSES MAKE THE DIFFERENCE

www.worlddiabetesday.org/nurses
#NursesMakeTheDifference

6 million more nurses needed